TC BioPharm (Holdings) PLC (TCBP)
0.6239
-0.01
(-0.94%)
USD |
NASDAQ |
Nov 22, 16:00
0.6199
0.00 (0.00%)
After-Hours: 20:00
TC BioPharm Cash from Financing (Quarterly): 1.183M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 1.183M |
| June 30, 2023 | 0.1979M |
| March 31, 2023 | 4.806M |
| Date | Value |
|---|---|
| September 30, 2021 | 5.392M |
| September 30, 2020 | 4.571M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
0.1979M
Minimum
Jun 2023
5.392M
Maximum
Sep 2021
3.23M
Average
4.571M
Median
Sep 2020
Cash from Financing (Quarterly) Benchmarks
| Adaptimmune Therapeutics PLC | 25.00M |
| Biodexa Pharmaceuticals PLC | -- |
| Verona Pharma PLC | -7.087M |
| NuCana PLC | -0.0888M |
| Autolus Therapeutics PLC | 0.185M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -3.055M |
| Cash from Investing (Quarterly) | -0.0071M |
| Free Cash Flow | -15.84M |
| Free Cash Flow Per Share (Quarterly) | -20.32 |
| Free Cash Flow Yield | -54.16K% |